Compare DEI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | VIR |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2006 | 2019 |
| Metric | DEI | VIR |
|---|---|---|
| Price | $12.38 | $8.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $12.94 | ★ $19.43 |
| AVG Volume (30 Days) | ★ 2.2M | 1.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.06% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,982,000.00 | $68,556,000.00 |
| Revenue This Year | $1.70 | $270.22 |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $9.04 | $4.16 |
| 52 Week High | $16.94 | $11.66 |
| Indicator | DEI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 36.75 |
| Support Level | $11.15 | $8.40 |
| Resistance Level | $12.70 | $10.33 |
| Average True Range (ATR) | 0.41 | 0.44 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 52.24 | 4.85 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.